Jump to section
To accelerate the discovery and development of therapeutics inspired by naturally-occurring molecules and traditional remedies, while preserving ethnobotanical knowledge and ecosystems.
Many science specialists will dream of helping the world by providing revolutionary medical treatment through bioscience innovation, but such ideas often come unmanifested due to a lack of funding and consultancy. Despite this, AI-driven precision medicine techniques provide fertile ground for new Medtech startups to be formed, showing great demand for medicine-focused venture incubators.
Pangea Botanica provides a medicine and therapeutics development incubator, offering scientists with the funding and resources necessary to develop new med-tech startups. The company focuses on supporting ideas that leverage AI to reveal unexplored biological systems, empowering a new generation of drug discovery technologies.
Whilst precision medicine startups are increasing in prevalence, these are generally born from Medtech giants, leaving aspiring science entrepreneurs without the necessary resources to compete. Pangea Botanica aims to democratise such innovations, demonstrating great potential through its first venture Kanna Health, which focuses on developing new therapeutics by exploring the sceletium tortuosum plant.
Steph
Company Specialist at Welcome to the Jungle
Lars Christian Wilde
(CEO)Experience as Co-founder, COO, and President of COMPASS Pathways from 2017 to 2021. Co-founder and Chairman of Kanna Health since 2021.
Manon Veraart
(CFO)Experience as Chief Business Officer for Quercis Pharma. Director at Kanna Health since 2021.
John Boghossian
(COO)Experience as Manager of Operations and Business Development, and Vice president of Operations for COMPASS Pathways from 2017 to 2020. CEO and Co-founder of Kanna Health since 2021.